Total Payments
$30,181
2023 Payments
$20.72
Companies
7
Transactions
29
Medicare Patients
168
Medicare Billing
$18,134
Payment Breakdown by Category
Consulting$12,145 (40.2%)
Other$9,790 (32.4%)
Travel$3,999 (13.3%)
Research$3,428 (11.4%)
Education$464.00 (1.5%)
Food & Beverage$353.81 (1.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $12,145 | 6 | 40.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5,290 | 4 | 17.5% |
| Honoraria | $4,500 | 2 | 14.9% |
| Travel and Lodging | $3,999 | 6 | 13.3% |
| Unspecified | $3,428 | 2 | 11.4% |
| Education | $464.00 | 1 | 1.5% |
| Food and Beverage | $353.81 | 8 | 1.2% |
Payments by Type
General
$26,752
27 transactions
Research
$3,428
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $7,773 | 13 | $0 (2018) |
| SCYNEXIS, Inc. | $7,525 | 1 | $0 (2022) |
| Mayne Pharma Inc. | $5,294 | 5 | $0 (2019) |
| PFIZER INC. | $5,290 | 4 | $0 (2018) |
| Astellas Pharma Global Development | $3,428 | 2 | $0 (2017) |
| Merck Sharp & Dohme Corporation | $850.00 | 3 | $0 (2020) |
| Aroa Biosurgery Incorporated | $20.72 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $20.72 | 1 | Aroa Biosurgery Incorporated ($20.72) |
| 2022 | $7,525 | 1 | SCYNEXIS, Inc. ($7,525) |
| 2020 | $100.00 | 1 | Merck Sharp & Dohme Corporation ($100.00) |
| 2019 | $3,287 | 4 | Mayne Pharma Inc. ($2,537) |
| 2018 | $12,196 | 14 | Gilead Sciences, Inc. ($5,460) |
| 2017 | $7,051 | 8 | Astellas Pharma Global Development ($3,428) |
All Payment Transactions
29 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 01/16/2023 | Aroa Biosurgery Incorporated | — | Food and Beverage | Cash or cash equivalent | $20.72 | General |
| 02/18/2022 | SCYNEXIS, Inc. | — | Consulting Fee | Cash or cash equivalent | $7,525.00 | General |
| 01/10/2020 | Merck Sharp & Dohme Corporation | NOXAFIL (Drug) | Consulting Fee | Cash or cash equivalent | $100.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/25/2019 | Merck Sharp & Dohme Corporation | NOXAFIL (Drug) | Consulting Fee | Cash or cash equivalent | $125.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 07/26/2019 | Mayne Pharma Inc. | TOLSURA (Drug) | Honoraria | Cash or cash equivalent | $2,000.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 07/26/2019 | Mayne Pharma Inc. | TOLSURA (Drug) | Travel and Lodging | Cash or cash equivalent | $536.96 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 03/29/2019 | Merck Sharp & Dohme Corporation | NOXAFIL (Drug) | Consulting Fee | Cash or cash equivalent | $625.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/30/2018 | Mayne Pharma Inc. | TOLSURA - 60 CAPSULE (Drug) | Honoraria | Cash or cash equivalent | $2,500.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/16/2018 | Gilead Sciences, Inc. | — | Travel and Lodging | In-kind items and services | $194.42 | General |
| 11/16/2018 | Gilead Sciences, Inc. | — | Travel and Lodging | In-kind items and services | $37.63 | General |
| 11/15/2018 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $9.53 | General |
| 11/14/2018 | Gilead Sciences, Inc. | — | Travel and Lodging | In-kind items and services | $37.63 | General |
| 11/06/2018 | PFIZER INC. | ERAXIS (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $780.00 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 11/03/2018 | Mayne Pharma Inc. | DORYX (Drug) | Food and Beverage | In-kind items and services | $184.51 | General |
| Category: DERMATOLOGY | ||||||
| 11/03/2018 | Mayne Pharma Inc. | DORYX (Drug) | Food and Beverage | In-kind items and services | $72.05 | General |
| Category: DERMATOLOGY | ||||||
| 10/10/2018 | Gilead Sciences, Inc. | — | Travel and Lodging | In-kind items and services | $2,999.03 | General |
| 07/13/2018 | PFIZER INC. | ERAXIS (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $3,200.00 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 06/18/2018 | Gilead Sciences, Inc. | AmBisome (Drug) | Consulting Fee | Cash or cash equivalent | $1,510.00 | General |
| Category: OTHER | ||||||
| 06/17/2018 | Gilead Sciences, Inc. | AmBisome (Drug) | Education | In-kind items and services | $464.00 | General |
| Category: OTHER | ||||||
| 06/17/2018 | Gilead Sciences, Inc. | AmBisome (Drug) | Travel and Lodging | In-kind items and services | $193.72 | General |
| Category: OTHER | ||||||
| 06/17/2018 | Gilead Sciences, Inc. | AmBisome (Drug) | Food and Beverage | In-kind items and services | $13.92 | General |
| Category: OTHER | ||||||
| 12/12/2017 | PFIZER INC. | ERAXIS (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $970.00 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 10/26/2017 | Astellas Pharma Global Development | Cresemba (Drug) | — | In-kind items and services | $824.50 | Research |
| Study: None • Category: Infectious Diseases | ||||||
| 09/20/2017 | Gilead Sciences Inc | AmBisome (Drug) | Consulting Fee | Cash or cash equivalent | $2,260.00 | General |
| Category: OTHER | ||||||
| 09/16/2017 | Gilead Sciences Inc | AmBisome (Drug) | Food and Beverage | In-kind items and services | $26.47 | General |
| Category: OTHER | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase III, Double Blind, Randomized Study to Evaluate Safety and Efficacy of BAL8557 Versus Voriconazole for Primary Treatment of Invasive Fungal Disease Caused by Aspergillus Species or Other Filamentous Fungi | Astellas Pharma Global Development | $2,604 | 1 |
| None | Astellas Pharma Global Development | $824.50 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 1 | 27 | 27 | $8,856 | $2,773 |
| 2021 | 2 | 51 | 52 | $15,969 | $4,977 |
| 2020 | 2 | 90 | 121 | $31,180 | $10,384 |
Total Patients
168
Total Services
200
Medicare Billing
$18,134
Procedure Codes
5
All Medicare Procedures & Services
5 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 27 | 27 | $8,856 | $2,773 | 31.3% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 37 | 38 | $12,497 | $4,017 | 32.1% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2021 | 14 | 14 | $3,472 | $959.18 | 27.6% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 57 | 60 | $20,318 | $6,473 | 31.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 33 | 61 | $10,862 | $3,912 | 36.0% |
About Dr. Thomas Patterson, MD
Dr. Thomas Patterson, MD is a Internal Medicine healthcare provider based in San Antonio, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/05/2006. The National Provider Identifier (NPI) number assigned to this provider is 1730198086.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Thomas Patterson, MD has received a total of $30,181 in payments from pharmaceutical and medical device companies, with $20.72 received in 2023. These payments were reported across 29 transactions from 7 companies. The most common payment nature is "Consulting Fee" ($12,145).
As a Medicare-enrolled provider, Patterson has provided services to 168 Medicare beneficiaries, totaling 200 services with total Medicare billing of $18,134. Data is available for 3 years (2020–2022), covering 5 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Infectious Disease
- Location San Antonio, TX
- Active Since 08/05/2006
- Last Updated 03/05/2019
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1730198086
Products in Payments
- ERAXIS (Drug) $5,290
- AmBisome (Drug) $4,468
- Cresemba (Drug) $3,428
- TOLSURA (Drug) $2,537
- TOLSURA - 60 CAPSULE (Drug) $2,500
- NOXAFIL (Drug) $850.00
- DORYX (Drug) $256.56
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in San Antonio
Hemal Nayak, Md, MD
Internal Medicine — Payments: $642,605
Internal Medicine $642,605
Dr. Allen Anderson, Md, MD
Internal Medicine — Payments: $444,990
Internal Medicine $444,990
Montaser Shaheen, M.d, M.D
Internal Medicine — Payments: $300,958
Internal Medicine $300,958
Shahid Aziz, M.d, M.D
Internal Medicine — Payments: $281,598
Internal Medicine $281,598
Dr. Ali Abedi, M.d, M.D
Internal Medicine — Payments: $257,382
Internal Medicine $257,382
Dr. Manuel Rodriguez, M.d, M.D
Internal Medicine — Payments: $187,632
Internal Medicine $187,632